UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
September 26, 2012
Date of Report (Date of earliest event reported)
CEPHEID
(Exact name of Registrant as specified in its charter)
California | 000-30755 | 77-0441625 | ||
(State or other jurisdiction of incorporation) |
(Commission file number) |
(I.R.S. Employer Identification No.) | ||
904 Caribbean Drive, Sunnyvale, CA | 94089 | |||
(Address of principal executive offices) | (Zip Code) |
(408) 541-4191
(Registrants telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 | Results of Operations and Financial Condition. |
On September 26, 2012, Cepheid issued a press release announcing preliminary revenue results for the quarter ended September 30, 2012. The press release is attached to this report as Exhibit 99.01.
The information in this report and the exhibit attached hereto are being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), nor shall they be deemed incorporated by reference in any filing with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference to such filing.
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits. |
Exhibit |
Exhibit Title | |
99.01 | Press release dated September 26, 2012. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CEPHEID | ||||||
Date: September 26, 2012 | By: | /s/ Joseph H. Smith | ||||
Name: | Joseph H. Smith | |||||
Title: | Senior Vice President, Business Development and General Counsel |
Exhibit List
Exhibit |
Exhibit Title | |
99.01 | Press release dated September 26, 2012. |
Exhibit 99.01
CONTACTS: | ||||
For Media Inquiries: | For Investor Inquiries: | |||
![]() |
Jared Tipton Cepheid Corporate Communications Tel: (408) 400 8377 communications@cepheid.com
|
Jacquie Ross Cepheid Investor Relations Tel: (408) 400 8329 investor.relations@cepheid.com
| ||
Cepheid 904 Caribbean Drive Sunnyvale, CA 94089 Telephone: 408.541.4191 Fax: 408.541.4192 |
CEPHEID ANNOUNCES PRELIMINARY 2012 THIRD QUARTER REVENUE RESULTS
Xpert® Cartridge Backorders to Ship in October, Full Year Revenue Guidance Unchanged
SUNNYVALE, California, September 26, 2012 Cepheid (Nasdaq: CPHD) today announced preliminary revenue results for the 2012 Third Quarter, ending September 30, 2012.
Based on current projections, Third Quarter revenue is expected to be in the range of $79 to $81 million, lower than targeted due primarily to intermittent interruptions in the supply of Xpert cartridge parts. The parts availability is being addressed and Cepheid is working aggressively to ship orders. However, the company currently expects to exit the quarter with more than $5 million in backorders expected to be fulfilled by the end of October.
Demand for our Xpert family of molecular tests continues to grow at a fast pace while we simultaneously scale-up our next generation manufacturing operations intended to support our anticipated cartridge demand, said John L. Bishop, Cepheids Chief Executive Officer. During the Third Quarter, parts issues arose as we were developing higher capacity production tools and processes, limiting our ability to manufacture at the volumes necessary to meet growing demand. We have notified customers that we are working diligently to fulfill orders as quickly as possible, but this will take several more weeks, pushing fulfillment of some orders from the Third Quarter into the Fourth Quarter.
Continued Bishop, Excluding this event, Cepheid would have been positioned to deliver total revenue in the range of $84 to $86 million. While there are still a few days left in the quarter, we expect total revenue will reflect a strong contribution from HBDC following the completion of the first buy-down agreement in early August and continued growth in commercial test sales, although we expect this strong performance will be partially offset by weaker US commercial system sales associated with a more challenging capital environment.
Based primarily on growing test demand, the company continues to expect total revenue to be in the range of $333 to $347 million for the full fiscal year ending December 31, 2012. The company will update its bottom line guidance during its regularly scheduled Third Quarter conference call on Thursday, 18 October, 2012.
Webcast of Cepheid Analyst Event
Cepheid will discuss this and other matters during its 2012 Analyst Event taking place in New York on Thursday, 27 September, 2012, starting at 8 a.m. Eastern Time. Cepheids Analyst Event is being webcast live, accessible from the companys website at http://ir.cepheid.com.
Cepheids Third Quarter Results Conference Call
With reference to the companys 2012 Third Quarter results, the company will host a management presentation at 2:00 p.m. Pacific Time on Thursday, October 18, 2012. To access the live webcast, please visit Cepheids website at http://ir.cepheid.com at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.
About Cepheid
Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the companys solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.
Forward-Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Cepheids or its managements intentions, beliefs, expectations and strategies for the future, including those relating to projected future revenues, both for the Third Quarter and Fiscal Year 2012, product sales under the High Burden Developing Country (HBDC) program, commercial test and commercial system sales, resolution of manufacturing scale-up issues and availability of parts supply. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the Companys current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our Third Quarter is not yet completed and actual Third Quarter results are subject to our standard quarterly close and review process; our ability to secure sufficient cartridge parts and increase manufacturing throughput of our cartridge production; long sales cycles and variability in systems placements and reagent pull-through in the Companys HBDC program; our success in increasing commercial and HBDC sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand and available capital budgets for our customers; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Companys ability to successfully introduce and sell products in clinical markets other than HAIs; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; other unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Companys reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Companys ability to manage geographically-dispersed operations; and underlying market conditions worldwide. Readers should also refer to the section entitled Risk Factors in Cepheids Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.
All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.
=_)IF9A@O`E=MKK$A)L6E`QC`-W`S%_=-50`E[OB:1B((H$`?=01<
MG*TBT![U#>Z)C!Z0<7\6[4X1V\[>&\986;A]D&6XD`+8*XF&W!^MU,'.;ZG5
MH*!>57+?+F\.>MS,VGLN*X=M[W2R&WB)K,X.[?=GID",6AWI:,\<5)GJ?X9\
M$ZYUA'.>^EKJ-AE(9L25=4R6F6T9A^EJ$+[Y4K%)O%FP7:42^`I&[&(G*)2I
MK^AAPKR!\D=U;UO#MKB^"XM[.4N:)6M)NI@XT]+6U]H&M:CU8C$+/?&_Q;V?
ML.R;N[EF>WENHFM>8'.`MHG`5/>X_P#;_2/2*=:+T=E_.]A3$S)7'FH%`9Y'
M=0R`Q3"V23)6H8G@T6Q3(($KD&T19S-@:MP`/;*0C!L(!Z',7G#L3XK[KW)*
MW5=_7+K&"0]SHQ^K)S[W&K6$Y8DN!Z*YW]\P=I;7B.B<;VC+V2-I:V4CVK
M9M,/0T`.`QS5MMLBFW1(BB0B:*92II))E*1-)),H$(DF0H`4A$REZ``!T``Z<
MT.!JYQ/U$X^9ZD^97H]&UC&!K,&`4'D%OY*K1PB.$1PB.$1PB.$1PB.$5;OS
M(98ROG_,^)/&YK^@[DI^Y_E-RR6V9JJ(MUP